Skip to main content
. 2013 Jul;94(Pt 7):1441–1450. doi: 10.1099/vir.0.051250-0

Fig. 4.

Fig. 4.

Efficacy and immunogenicity of rMP12-TOSNSs in CD1 mice. (a) Schematics of vaccination and challenge schedule. CD1 mice mock-vaccinated with PBS or vaccinated with MP-12 or rMP12-TOSNSs (1×105 p.f.u., s.c.) were i.p. challenged with 1×103 p.f.u. of wt RVFV ZH501 strain at day 45 post-vaccination and observed for 21 days. (b) Kaplan−Meier survival curves of CD1 mice challenged with ZH501 strain. (c) Neutralizing antibody (plaque reduction neutralization test, PRNT80) titre at day 42 post-vaccination. Asterisk (*) represents dead mice after wt RVFV challenge. (d) Titre of anti-N IgG measured by IgG ELISA at day 42 post-vaccination. Asterisk (*) represents dead mice after wt RVFV challenge. (e) Anti-RVFV NSs IgG measured by IgG ELISA at day 42 post-vaccination (before wt RVFV challenge) and day 21 post-wt RVFV challenge. Note that this IgG ELISA does not distinguish antibodies to ZH501 NSs or MP-12 NSs. Optical density (OD405) values for 1:100 of each serum sample were plotted. The cut-off value (0.193) is shown as a dotted line.